# Ultima Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ultima-genomics

- Industry: Biotechnology
- Headquarters: Fremont, US
- Website: www.ultimagenomics.com
- Total disclosed funding: $31M
- Latest round: Series A (Dec 28, 2017)
- Investors on record: 3

## About

Ultima Genomics, Inc. focuses on developing innovative DNA sequencing solutions aimed at enhancing genomic research accessibility and efficiency. Founded in 2016 and headquartered in California, US, Ultima Genomics, Inc. specializes in DNA sequencing technology. The company has undergone strategic developments to enhance its product offerings and has secured funding from major investors, including Andreessen Horowitz and Khosla Ventures. The founder, Gilad Almogy, is also the CEO, bringing a wealth of experience in the genomics sector. Ultima Genomics has completed three funding deals, with the latest round in which they raised USD 600.00 mn, serving as a strong financial backing for their growth initiatives. Ultima Genomics specializes in high-throughput and cost-effective DNA sequencing solutions, primarily through its flagship product, the UG 100 Sequencing Platform. This innovative platform utilizes advanced sequencing architecture designed to enhance throughput and reduce costs, addressing key challenges in the genomics industry, such as scalability and accessibility of sequencing technologies. The UG 100 allows for the generation of up to 12 billion reads per wafer, enabling the analysis of over 30,000 genomes annually. The company's offerings also include the Solaris library prep workflows and bioinformatics analysis tools, which are optimized for seamless integration with third-party library preparation providers. Ultima Genomics serves a diverse clientele, including research institutions, clinical laboratories, and biopharmaceutical companies across various geographical markets, including North America, Europe, and Asia. Ultima Genomics generates revenue primarily through the sale of its UG 100 Sequencing Platform and associated services, including sequencing runs and library preparation workflows. The company's business transactions occur predominantly on a B2B basis, with clients engaging in partnerships and collaborative projects to leverage Ultima's sequencing technology for various genomic research applications. Pricing structures are based on service agreements and may involve transaction models that include pay-per-sequencing run or subscription packages for ongoing access to sequencing services and support. The UG 100 platform and Solaris workflows are key revenue drivers, as clients utilize these tools for applications in whole genome sequencing, oncology research, and proteomics, enabling them to achieve advancements in genomic science and personalized medicine.

## Funding rounds

- Series A, Dec 28, 2017, $31M — Playground Ventures
- Seed, Jun 1, 2016 — Lightspeed Venture Partners, Khosla Ventures

## Investors

- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Seed
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Seed
- Playground Ventures (https://capitalatlas.ai/funds/playground-ventures) — Series A